文献速递血栓与止血

海曲泊帕治疗免疫性血小板减少症的减量至停药阶段及长期疗效与安全性:一项开放标签扩展研究结果

Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study.
PubMed 文献 · J Thromb Haemost · 2021-12-15

本研究基于Ⅲ期试验(NCT03222843)报告海曲泊帕治疗中国免疫性血小板减少症患者的减量至停药阶段(≤6周)及额外24周长期扩展期数据。194例进入减量阶段患者中171例(88.1%)复发,首次复发中位时间15.0天(95%CI 14.0-16.0)。长期治疗可有效提升并维持血小板计数,耐受性良好。

要点

  • 减量至停药阶段194例中171例(88.1%)复发,首次复发中位时间15.0天(95%CI 14.0-16.0)
  • 长期扩展期海曲泊帕组339例中144例(42.5%)在≥75%评估中应答
  • 海曲泊帕组254例(74.9%)至少一次达到血小板计数≥30×10^9/L且≥基线2倍

核心结论

  • 多数经历减量至停药的患者出现复发,长期海曲泊帕治疗可有效提升并维持中国成人免疫性血小板减少症患者血小板计数于目标范围,且耐受性良好。

研究设计与样本

  • 基于随机、双盲、安慰剂对照、多中心Ⅲ期试验(NCT03222843)的开放标签扩展研究,报告≤6周减量至停药阶段(Stage 3)及额外24周长期扩展期(Stage 4)数据;符合筛选标准的患者可进入Stage 3或4。

主要发现

  • 进入Stage 3的194例患者中171例(88.1%)复发,自Stage 3开始至首次复发的中位时间为15.0天(95%CI 14.0-16.0)。
  • Stage 4中海曲泊帕组(n=339)144例(42.5%)在≥75%的评估中应答,254例(74.9%)至少一次达到血小板计数≥30×10^9/L且至少为基线血小板计数的2倍。
  • 海曲泊帕组最常见不良事件为上呼吸道感染(53.1%)、血小板减少症(27.1%)和尿路感染(21.2%)。

关键数值与推荐

  • Stage 4中海曲泊帕起始剂量为2.5、3.75、5或7.5 mg每日一次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of hetrombopag in Chinese patients with immune thrombocytopenia (ITP) has been demonstrated in a randomized, double-blind, placebo-controlled, multicenter, phase III trial (NCT03222843). OBJECTIVE: This study aimed to report comprehensive data on a ≤6-week dose tapering to withdrawal (Stage 3) and an additional 24-week long-term extension period (Stage 4) in this phase III trial. PATIENTS/METHODS: Patients who fulfilled the screening criteria were eligible to enter Stage 3 or 4. During Stage 3, hetrombopag was gradually tapered to withdrawal. During Stage 4, hetrombopag treatment was initiated at 2.5, 3.75, 5, or 7.5 mg once daily. The efficacy endpoints during Stage 3 or 4 and the safety profile during the entire treatment period were reported. RESULTS: Among 194 patients who entered Stage 3, 171 (88.1%) relapsed. The median time to the first relapse since the start of Stage 3 was 15.0 days (95% CI, 14.0-16.0). In Stage 4, 144 (42.5%) patients responded at ≥75% of their assessments and 254 (74.9%) patients achieved platelet count ≥30 × 109 /L at least once, which was at least twice their baseline platelet count in the hetrombopag group (n = 339). The most common adverse events were upper respiratory tract infection (53.1%), thrombocytopenia (27.1%), and urinary tract infection (21.2%) in the hetrombopag group. CONCLUSION: The majority of patients who experienced dose tapering to withdrawal experienced a relapse. Long-term treatment with hetrombopag was effective in increasing and maintaining platelet count within the desired range in Chinese adults with ITP. Hetrombopag was well tolerated.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mei H, Liu X, Li Y, et al. Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study. J Thromb Haemost. 2021. PMID: 34821020. doi:10.1111/jth.15602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。